ClinicalTrials.gg
Not yet recruitingNCT06934616Updated Apr 30, 2025

A Phase I, First-in-Human Study of GB268 (PD-1/CTLA-4/VEGF Trispecific Antibody) in Advanced Solid Tumors

A Phase 1 interventional study of GB268 in Solid Tumor Cancer, sponsored by Genor Biopharma Co., Ltd.. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-30.

Sponsored by Genor Biopharma Co., Ltd. (part of Edding Genor Group Holdings Limited) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
330
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is a Phase I, First-in-Human, Open-Label, Multicenter Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of a Trispecific PD-1/CTLA-4/VEGF Antibody GB268 in Participants with Advanced Solid Tumors. The study will consist of a dose-escalation stage and an dose-expansion stage.

02

Conditions studied

  • Solid Tumor Cancer

Keywords

  • PD-1
  • CTLA-4
  • VEGF
  • anti-PD-1/CTLA-4/VEGF trispecific antibody
  • advanced solid tumors
  • Phase I
03

In context

Lead sponsor

Genor Biopharma Co., Ltd. is the lead sponsor of 24 studies on the registry; 4 are open to participants now.

First submitted before Genor Biopharma Co., Ltd. became part of Edding Genor Group Holdings Limited.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. ≥ 18 years of age at the time of .
  2. Able to give voluntary informed consent and are willing to follow and complete all the study required procedures.
  3. Participants with or cytologically confirmed locally advanced, or unresectable solid tumors that have failed standard therapy, or for whom no standard therapy exists, or where standard therapy is .
  4. Participants must have according to Response Criteria in Solid Tumors () v1.1.
  5. performance status ≤ 1.
  6. Participants with HCC must have a score class A.
  7. ≥ 3 months.
  8. Participants must have adequate organ function
  9. Tumor tissue samples for biomarker testing are highly desirable (mandatory in dose expansion part)
  10. For women of : participants must have a negative serum pregnancy test within 7 days prior to Cycle 1 Day 1 and agree to abstain from heterosexual intercourse or use an acceptable method during the study and for at least 6 months following the final administration of GB268.
  11. For male participants: agreement to abstain from heterosexual intercourse or use of an acceptable contraceptive method during the study treatment and for at least 6 months following the final infusion, and agreement to refrain from sperm donation during the study treatment and for at least 6 months following the final administration of GB268.

Exclusion criteria

Exclusion Criteria:

  1. Received the following treatments or medications before starting the study treatment:

    1. Participants who received the last systemic anti-tumor therapy, including chemotherapy, biological agents etc., within 3 weeks prior to Cycle 1 Day 1; participants who received hormonal anti-tumor therapy and small molecule targeted therapy within 2 weeks prior to Cycle 1 Day 1; and participants who received Chinese herbal medicine or traditional Chinese medicinal products with anti-tumor indications within 2 weeks prior to Cycle 1 Day 1. Participants who received non-specific immunomodulatory therapy (e.g., interleukin, interferon, thymosin, tumor necrosis factor, etc.) within 2 weeks prior to Cycle 1 Day 1.
    2. Received a live or attenuated vaccination within 4 weeks prior to Cycle 1 Day 1.
    3. Prior radiation therapy completed within 3 weeks prior to Cycle 1 Day 1. Palliative radiotherapy for the control of symptoms is allowed to be completed at least 2 weeks prior to Cycle 1 Day 1.
  2. Treatment with systemic medications within 2 weeks prior to Cycle 1 Day 1.
  3. Participants who have, or will have, any of the following:

    1. An invasive operative procedure within 4 weeks of, or with incomplete recovery, before Cycle 1 Day 1. Participants who have undergone minor local procedure (excluding peripherally inserted central catheterisation and intravenous infusion port implantation) within 3 days prior to Cycle 1 Day 1.
    2. Significant traumatic injury within 4 weeks prior to Cycle 1 Day 1 (all wounds must be fully healed prior to Cycle 1 Day 1).
    3. Any medical condition that affects wound healing capacity and is expected to endanger participant safety if wound healing capacity would be severely reduced during administration of the product.
    4. Major surgery expected during study participation.
  4. Unresolved toxicities from prior anti-cancer therapy, defined as having not resolved to Grade ≤ 1
  5. Participants who have experienced ≥ Grade 3 immune-related adverse events (irAE) or irAE leading to treatment discontinuation
  6. Has known active central nervous system (CNS) .
  7. Participants with a history of other unless the patient has undergone potentially curative therapy with no evidence of that disease for 3 years prior to Cycle 1 Day 1
  8. Uncontrolled pleural effusion, or ascites requiring recurrent drainage procedures within 4 weeks prior to Cycle 1 Day 1.
  9. History of cardiovascular disease.
  10. History of interstitial lung disease (ILD).
  11. Active or prior documented disease required systemic treatment within the past 2 years.
  12. Active or prior history of inflammatory bowel disease (such as Crohn's disease, ulcerative colitis, or chronic diarrhea).
  13. Prior history of hypertensive crisis or hypertensive encephalopathy.
  14. Participants with significant coagulation disorders or other obvious evidence of bleeding risk.
  15. History of abdominal fistula, tracheoesophageal fistula, and female genital fistula (e.g., vesicovaginal fistula, urethrovaginal fistula, and vesicocervical fistula, etc.), gastrointestinal perforation, or abdominal abscess, or patient has risk factors for gastrointestinal obstruction at the discretion of the investigator.
  16. Active infection that have received systemic anti-infective treatment within 2 weeks prior to Cycle 1 Day 1. Serious infections within 4 weeks prior to Cycle 1 Day 1, including but not limited to complications requiring hospitalization, sepsis or severe pneumonia.
  17. Participants with uncontrolled concurrent illness, including, but not limited to, poorly controlled hypertension or Type 2 diabetes mellitus, or psychiatric illness or a social situation that would limit compliance with the study requirements.
  18. Known presence of active tuberculosis.
  19. Participants have at screening:

    1. Positive (hepatitis B virus [HBV]) surface antigen (HBsAg) or Hepatitis B Core Antibody (HBcAb), with HBV-DNA result greater than 500 IU/mL (or 2500 copies/mL).
    2. Positive virus antibody (anti-HCV), with HCV-RNA result greater than the lower limit of quantification.
  20. History of primary immunodeficiency. Participants who have previously been positive for (HIV) antibody, or are positive for HIV at screening.
  21. History of solid organ or blood system transplantation, except for corneal transplantation.
  22. Female patients who are pregnant, or breast-feeding.
  23. Patients with known allergies, , or intolerance to GB268 or its . Patients with history of severe hypersensitivity reactions to other mAbs.
  24. Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
330 participants (estimated)

Study arms

  • Experimental
    GB268

    Drug: GB268

Interventions

  • DrugGB268

    GB268 will be administered via intravenous infusion once every 3 weeks on Days 1 of each 21-day cycle

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events (AEs)

    Safety as assessed by clinical laboratory tests, 12-lead electrocardiogram (ECG), vital signs measurements, and the incidence, nature and severity of all adverse events (AEs) and serious AEs (SAEs)

    Time frame: Up to approximately 2 years

  2. Dose Limiting Toxicity (DLT)

    Incidence of Dose Limiting Toxicity (DLT) during the first cycle of treatment

    Time frame: 21 days

Secondary outcomes

  1. ORR

    objective response rate assessed by investigator per RECIST v1.1

    Time frame: Up to approximately 2 years

  2. DOR

    duration of response assessed by investigator per RECIST v1.1

    Time frame: Up to approximately 2 years

  3. DCR

    disease control Rate assessed by investigator per RECIST v1.1

    Time frame: Up to approximately 2 years

  4. PFS

    progression free survival assessed by investigator per RECIST v1.1

    Time frame: Up to approximately 2 years

  5. Cmax of GB268

    Peak plasma concentration

    Time frame: Up to approximately 2 years

  6. Tmax of GB268

    Time to peak drug concentration

    Time frame: Up to approximately 2 years

  7. AUC of GB268

    Area under curve

    Time frame: Up to approximately 2 years

  8. ADA of GB268

    Detection of anti-GB268 antibodies

    Time frame: Up to approximately 2 years

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Apr 2025; primary completion for Mar 2027, 23 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2025
First posted
Apr 18, 2025
StartEst.
Apr 24, 2025
Primary completionEst.
Mar 2027
CompletionEst.
Mar 2028
Last update
Apr 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06934616
Responsible party
Sponsor
First posted
Apr 18, 2025
Start date
Apr 24, 2025 (estimated)
Primary completion
Mar 2027 (estimated)
Completion
Mar 2028 (estimated)
Last update
Apr 30, 2025

Study contacts

Zhigang Yan, Bachelor
Contact
zhigang.yan@genorbio.com
86-18310577427

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion